ImpediMed to Present Chronic Breast Cancer-related Lymphedema Study Results at American Society of Breast Surgeons Annual Meeting

New research shows patients at risk of developing breast cancer-related lymphedema should be monitored for minimum of three years following completion of cancer treatment CARLSBAD, Calif., April 11, 2024 /PRNewswire/ — ImpediMed, a leader in medical technologies to clinically monitor and…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks